John L. Lamattina
Director · LIGAND PHARMACEUTICALS INC
- 2024
- Jun 12, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies John L. Lamattina files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Octavio Espinoza - $13.03M in LGND purchases and sales in the last 12 months
- Andrew Reardon - $10.29M in LGND purchases and sales in the last 12 months
- Jason Haas - $3.74M in LGND purchases and sales in the last 12 months
- Nancy Ryan Gray - $1.35M in LGND purchases and sales in the last 12 months
- Jason Aryeh - $1.25M in LGND purchases and sales in the last 12 months
- Stephen L. Sabba - $1.16M in LGND purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is John L. Lamattina?
John L. Lamattina is a corporate insider, tracked as Director of LIGAND PHARMACEUTICALS INC (LGND). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did John L. Lamattina last file a Form 4?
The most recent primary Form 4 on record is dated 12 June 2026, one of 6 filings going back to 2024.
Has John L. Lamattina been buying or selling stock?
Recorded transactions: 0 open-market purchases and 8 open-market sales ($2.74M) across all tracked filings.
